Three cysteines in human recombinant folylpoly-␥-glutamate synthetase (FPGS) that were reactive with iodoacetamide were located in peptides that were highly conserved across species; the functions of two of these peptides, located in the C-terminal domain, were studied by site-directed mutagenesis. When cDNAs containing mutations in each conserved ionic residue on these peptides were transfected into AUXB1 cells, which lack endogenous FPGS activity, one mutant (D335A) did not complement the auxotrophy, and another (R377A) allowed only minimal growth. FPGS activity could not be detected in insect cells expressing abundant levels of these two mutant proteins from recombinant baculoviruses nor from a virus encoding an H338A mutant FPGS. Kinetic analysis of the purified proteins demonstrated that each of these three mutants was quite different from the others. The major kinetic change detected for the H338A mutation was a 600-fold increase in the K m for glutamic acid. For the D335A mutation, the binding of all three substrates (aminopterin, ATP, and glutamic acid) was affected. For R377A, the K m for glutamic acid was increased by 1500-fold, and there was an Ϸ20-fold decrease in the k cat of the reaction. The binding of the K ؉ ion, a known activator of FPGS, was affected by the D335A and H338A mutations. We conclude that these three amino acids participate in the alignment of glutamic acid in the active site and that Arg-377 is also involved in the mechanism of the reaction.
Folates enter mammalian cells as pteroylmonoglutamates, but are rapidly metabolized by the addition of 4 -8 mol of glutamic acid through amide bonds, forming a long ␥-linked side chain. Polyglutamation constitutes a mechanism to trap folates within mammalian cells; the long chain folylpolyglutamates are poorly accepted by the membrane carriers responsible for efflux. The enzyme that catalyzes the synthesis of these polyglutamates, folylpoly-␥-glutamate synthetase (FPGS), 1 is found in both the cytoplasm and the mitochondria of mammalian cells (1, 2) ; but both species of enzyme are transcribed from the same gene, and the two translated forms differ only by the presence of a leader peptide required for tracking to and penetration of the mitochondria (2) . Interestingly, alternate exon usage is not involved in the mechanism whereby the two mRNA species encoding the cytosolic and mitochondrial forms of this enzyme are produced, but rather, alternate transcriptional start sites are used on the same first exon under the control of a TATA-less promoter (2) . The study of FPGS has lagged behind the interest in and importance of this enzyme, in large part because of the low levels of enzyme present in even the richest endogenous source. However, with the cloning of the cytosolic (3) and mitochondrial (2) forms of FPGS from human leukemic cells, heterologous expression has allowed access to substantial levels of this protein for the first time. We have presented a preliminary report (4) describing purification of recombinant human leukemic cell cytosolic FPGS expressed in insect cells to typical yields of 5-25 mg/liter of culture. Such quantities of FPGS now allow direct studies on the mechanism of the FPGS reaction and the characteristics of the active site.
The FPGS found in the cytoplasm of CEM human leukemic cells contains 545 amino acids. In our initial attempts to locate the active site of rhcFPGS, we noted the presence of three highly reactive, solvent-exposed cysteines that were protected from iodoacetamide by ATP, one of the substrates for the FPGS reaction. Each of the cysteines was adjacent to regions of the protein in which several amino acids have been conserved in the several species of FPGS now sequenced, which range from bacteria, through yeast and lower multicellular eukaryotes, to higher mammals. To determine the function of these peptides directly, we have mutated each of six highly conserved charged residues within these domains. We now report that the mutation of three of these amino acids induced substantial changes in the kinetic properties of FPGS, consistent with the hypothesis that they are located in the active site of this enzyme. A recently published (5) x-ray structure of the Lactobacillus casei FPGS to which was bound Mg-ATP, but not folate or glutamic acid, allowed a partial visualization of the ATP binding site. This paper now allows a more detailed placement of the active site of FPGS within this structure.
MATERIALS AND METHODS

Expression and Purification of Wild-type and Mutant rhcFPGS-A
cDNA encoding cytosolic rhFPGS was ligated into the plasmid vector pBlueBacIII to give the baculoviral transfer vector phcFPGS, and a recombinant baculovirus was produced by recombination of phcFPGS with linearized wild-type AcMNPV baculoviral DNA in Sf9 cells. The starting FPGS cDNA was from CEM leukemia cells (2) and extended from the more downstream of the two start methionines up to 200 bp into the 3Ј-untranslated region. The expression and purification of wild-type recombinant FPGS will be described in detail elsewhere.
Each mutated cDNA construct in pBluebac III (3 g) was mixed with 1 g of linearized Bac-N-Blue viral DNA (Invitrogen) and lipofected into 2.5 ϫ 10 6 Sf9 insect cells. After 100 h, supernatants were used for plaque purification of viruses. Blue plaques without occlusion bodies were chosen, and initial viral stock was checked for purity by PCR as described by Invitrogen. One highly expressing virus for each mutant was then further amplified and used for production of the protein.
Wild-type and mutant enzymes were purified by a three-step procedure consisting of ammonium sulfate fractionation and chromatography on a Sephacryl S-100 HR column followed by gradient elution of a DEAE-Sephacel column. Purified rhcFPGS was estimated to be Ͼ95% pure by electrophoresis of overloaded SDS-polyacrylamide gels (Fig. 1) , and all of the mutant proteins behaved similarly to the wild-type FPGS during this purification procedure. Purified proteins were stored at Ϫ25°C in 50% glycerol. During kinetic studies for estimation of the K m value of ATP, a very high background was observed, suggesting contamination of the concentrated protein with ATP. A PD10 gel filtration column (Amersham Pharmacia Biotech) removed the contaminant.
Mutagenesis-Alanine mutants at positions Asp-335, His-338, Cys-346, Asp-376, Arg-377, Asp-378, and Lys-384 (numbered considering the cytosolic start codon (2) as ϩ1) were constructed by a modification of a PCR-based method (6) . The procedure uses three primers, two gene-specific (one forward, 5Ј-GAGCCAAAGGCATCCAGGCCAGGGC-T-3Ј; and one reverse, 5Ј-TTCGTCCAGGTGGTTCCAGTGC-3Ј) and a third forward-mutated primer. The mutating primers were designed to either generate or delete a restriction site to allow for efficient analysis of mutants and were 5Ј-phosphorylated. These primers were as follows: for D335A, 5Јp-CTCACCTGGTATCTGGCCGGTG-CGCA-3Ј; for H338A, 5Јp-CTGGACGGTGCAGCCACCGCCAGCA-3Ј; for C346A, 5Јp-AGCGCGCAGGCCGCTGTGCGCTGGTTC-3Ј; for D376A, 5Јp-AATGC-TACCGGTGCCCGGGACCCGGC-3Ј; for R377A, 5Јp-AATGCTACCGG-CGACGCGGACCCGGCG-3Ј; for D378A, 5Јp-TACCGGGGACCGGGC-ACCGGCGGCCCT-3Ј; and for K384A, 5Јp-GGCCCTGCTGGCGCTGC-TGCAGCCCT-3Ј. (The nucleotides that have been changed are underlined, and those responsible for the mutation are listed in boldface.) Five ng of phcFPGS was used as the template, and the mutated and unmutated primers were 7.5 and 0.75 M, respectively. Deoxyribonucleoside triphosphates (0.2 mM), MgCl 2 (1.5 mM), NAD (1 mM), dithiothreitol (1 mM), Taq polymerase (Promega, Madison, WI) (1.25 units), and Taq ligase (New England Biolabs, Beverly, MA) (10 units) were added in a 25-l reaction volume using Taq polymerase buffer (Promega). The PCR cycle conditions used were as follows: 95°C for 3 min followed by 95°C for 1 min, 56°C for 2 min, and 65°C for 4 min. The product was amplified for 29 cycles, and the final elongation step was 10 min at 65°C to ensure the incorporation of the mutated primer. Two products were obtained, a short product extending from the mutated primer to the reverse primer and the longer product (460 bp) from the gene-specific forward primer to the reverse primer. For those mutant sequences in which a unique restriction site was deleted (for D335A, a KpnI site; for H338A, a FspI site; for C346A, a StuI site), the 460-bp PCR fragment was enriched for mutated products by endonuclease digestion prior to purification. The 460-bp PCR product was digested with ApaI and TthIII to generate a 270-bp fragment, which was cloned into similarly digested phcFPGS. The entire ligation mixture was precipitated with ethanol and transfected into XL1-blue cells. The PCRgenerated regions of the resultant clones were manually sequenced to confirmed the presence of mutations.
Functional Complementation of AUXB1 Cells by FPGS MutantsMutant cDNAs constructed in pBluebac III were excised as a 1.7-kilobase BstEII/XbaI fragment and ligated into hcFPGS cDNA in the pcDNA3 (Invitrogen) vector cut with the same enzymes, generating FPGS cDNAs which initiate at the cytosolic start methionine and extend 100 bp into 3Ј-untranslated region. AUXB1 cells were plated at 2 ϫ 10 5 cells per 100-mm dish in ␣ ϩ medium and then overlaid the next day with 5 g of cDNA constructs mixed with 5 g of pY3, which encodes the hygromycin B resistance marker (7), as a mixed calcium phosphate precipitate (8) in a final volume of 1 ml. Double selection with ␣-medium formulated without nucleosides (␣ Ϫ ) and with hygromycin B at 400 g/ml was applied 4 days after transfection (2) . Colonies were fixed, stained, and scored on day 15 .
Inhibition and Radiolabeling of rhcFPGS by Iodoacetamide (IAM)-A 50% glycerol stock of rhcFPGS was passed through a PD-10 gel filtration column equilibrated with labeling buffer (20 mM Na-HEPES, 10 mM MgCl 2 , and 20 mM KCl, pH 7.5 (at 25°C)). The enzyme (174 pmol in 0.4 ml) was incubated in labeling buffer at 20°C for 5 min before the addition of 2 mM IAM in the presence or absence of ATP (3 mM) with or without methotrexate (2 mM).
For stoichiometry studies, 1 nmol of rhcFPGS was preincubated at 20°C for 5 min in 175 l of labeling buffer prior to the addition of 350 nmol of [ 14 C]IAM (8.63 cpm/pmol). The reaction was stopped by the addition of 2-ME to 50 mM, enzyme activity was determined, and solid urea was added to 8 M. The resulting clarified solution was applied to 25-mm Immobilon-P membrane discs, and the membranes were washed with 50 ml of 20% methanol containing 50 mM Tris-HCl buffer, pH 8.7 (at 25°C). A standard amount of [ 14 C]IAM was spotted onto membranes and counted under identical conditions to allow conversion of proteinbound 14 C to pmol of bound IAM. Filtration of reaction mixes through two stacked membranes and subsequent staining with Coomassie Blue indicated that less than 3% of the FPGS applied was penetrating to the second disc.
Tryptic Digestion of rhcFPGS Labeled with [
14 C]IAM-rhcFPGS (5.5 nmol in 0.65 ml) was labeled with 2 mM [ 14 C]IAM at 20°C for 12 min as described above. 2-ME was added to a concentration of 50 mM, and the solution was brought to 50% in ethanol. The precipitate was washed three times with alcohol and water to remove excess label and was then dissolved in 100 l of 8 M urea in 0.4 M NH 4 HCO 3 , pH 8. Dithiothreitol (0.45 mol in 10 l) was added, and the tube was kept at 50°C for 15 min. Nonradioactive IAM (1 mol in 10 l) was added, and the mixture was incubated for another 15 min at room temperature. The concentration of urea was adjusted to 2 M in 0.1 M NH 4 HCO 3 . Trypsin was added at a ratio of 1:20 (w/w), and the mixture was incubated at 37°C for 72 h with the addition of a second aliquot of trypsin at 36 h. For the purpose of exhaustive peptide analysis, the tryptic digest was subjected to HPLC on a C-8 column, and all radioactive peaks eluting after 20 min were lyophilized, redissolved in 2 M urea/100 mM NH 4 HCO 3 , pH 8.0, and digested for another 48 h with trypsin at a ratio of 1:1 (w/w). For peptide purification and analysis, the enzyme was reacted with IAM for 12 min to a stoichiometry of 3:1 bound IAM:FPGS, and the tryptic digestion of the labeled protein was carried out at 37°C in 2 M urea containing 0.1 M NH 4 HCO 3 , pH 8.3, at 1:10 (w/w) trypsin to rhcFPGS.
Purification and Identification of Labeled Peptides-The labeled peptides were purified by reverse phase HPLC using a 300-Å Whatman C-8 column (4.6 ϫ 250 mm) at a flow rate of 1 ml/min. The digest was applied as a 0.08% trifluoroacetic acid solution, and the peptides were eluted using a gradient of trifluoroacetic acid in acetonitrile. The elution of peptides was monitored at 220 nm; 0.5-min fractions were collected and analyzed for radioactivity by scintillation counting. Radioactive peptides corresponding to peaks I, II, and III, which eluted after 21, 13.5, and 25.3 min, respectively, were combined from several experiments, lyophilized, and dissolved in 2 M urea in 0.1 M NH 4 HCO 3 , pH 8.3. Each peak was further purified by HPLC using a Whatman 300-Å C-18 column (4.6 ϫ 250 mm) eluted with gradients of acetonitrile at a flow rate of 0.8 ml/min. The peptides pooled from the C-8 column were each chromatographed twice on a C-18 column as 0.08% trifluoro-FIG. 1. SDS gel electrophoresis of purified rhcFPGS. rhcFPGS (10 g) expressed and purified as described in the text was precipitated with 10% trichloroacetic acid, redissolved in SDS-polyacrylamide gel electrophoresis sample buffer, and loaded onto a 10% polyacrylamide gel. The gel was subsequently stained with Coomassie Blue. The samples were as follows: lane 1, molecular mass markers; lane 2, rhcFPGS. acetic acid solutions, after which a single peak eluted that had coincident profiles of A 220 and 14 C. Pools of each peptide were submitted for microsequencing and mass spectrometry at 1-2 nmol/0.2 ml.
Peptide Microsequencing and Mass Spectrometry-HPLC-purified peptides were subjected to automated Edman degradation on a Hewlett Packard G1005A protein sequencer at Commonwealth Biotechnologies Inc. (Richmond, VA). The effluent from individual cycles of HPLC was concentrated, and 14 C was determined. Peptides were also analyzed in a Nermag 30-10 triple quadrupole mass spectrometer equipped with an Analytica electrospray ionization source (Branford, Inc.). Samples were diluted in a 50% methanol solution containing 0.5% acetic acid and injected at a flow rate of 1 l/min using CO 2 for counter-current drying. The temperature of the CO 2 at the heater was 250°C. For each sample, several mass spectra were acquired over m/z ϭ 3-1600 in 9 s . These analyses were kindly performed by Dr. John Fenn and associates (9) 3 H]aminopterin (Moravek Biochemicals) was dried and reconstituted in Buffer A. When used as a fixed substrate, ATP was held at 5 mM, glutamic acid at 400 mM, and aminopterin was held constant between 100 and 500 M. As a variable substrate, the concentration of aminopterin was varied between 2.5 and 400 M, ATP was varied between 2 and 1000 M, and glutamic acid ranged from 12 mM to 400 mM. Assays were carried out at 37°C and were stopped by a 2 min incubation at 100°C. Double-strength tetrabutylammonium hydrogen sulfate buffer (Low UV PicA reagent; Waters Corp., Milford, MA) was added and the reaction mixtures were centrifuged at 14,000 rpm for 5 min. Sep-pak C18 cartridges (Waters Corp.) were washed with methanol and equilibrated in PicA prior to loading the centrifuged reaction mixtures. The cartridges were washed with 3 ml of PicA buffer and then with 3 ml of 90% PicA, 10% methanol; reaction products were centrifugally eluted with 500 l of 60% methanol. The eluant was dried, and the residue was reconstituted in 100 l of PicA. This solution was passed through a 0.2-m filter (Gelman), and 80 l of the filtrate was injected onto a 4.6 ϫ 100 mm, 3-m, C 18 reverse phase Luna column (Phenomenex, Torrance, CA). A two-phase linear gradient of methanol/ PicA (pH 6.0) was used: 20 -28% methanol over 10 min followed by an increase to 36% methanol over 15 min. The eluant was monitored at 304 nM, and the peak corresponding to aminopterin diglutamate was collected as 20-s fractions. The specific activity of aminopterin was determined by HPLC. The data were fit to the Michaelis-Menten equation using Enzfitter software (Elsevier Biosoft).
Polyglutamation of (6R)-DDATHF in Vitro-Reactions were initiated at 37°C by the addition of 2.5 g of FPGS to 5 M DDATHF (or its dior triglutamate derivatives), 5 mM ATP, 10 mM MgCl 2 , 5 mM glutamic acid, 30 mM KCl, 0.15 mg/ml bovine serum albumin, and 50 mM 2-ME in a total volume of 500 l of 100 mM Tris buffer, pH 8.9, and terminated at 100°C for 2 min. The samples were prepared for HPLC as above, but eluants from Sep-pak columns were reconstituted in 200 l of PicA buffer. A 50-l aliquot was injected onto a Luna column eluted with mobile phase consisting of multiphase gradients of PicA and methanol; an initial methanol concentration of 27% was increased to 35% in 10 min, followed by an increase to 42% in the next 15 min, and was then held at 42% for another 10 min. The identity of peaks was confirmed by coinjection with standards that were generously provided by Dr. Chuan Shih (Lilly).
Effect of Potassium on the Activity of rhcFPGS and Its Mutants-In these experiments, the stock solutions of glutamic acid and aminopterin were dissolved in Tris buffer. The final strength of Tris buffer was 0.5 M at pH 8.9. Reactions contained 0.4 M glutamic acid, 0.5 mM aminopterin, 5 mM ATP as the Tris salt, 10 mM MgCl 2 , 50 mM 2-ME, and bovine serum albumin at 0.6 mg/ml in a reaction volume of 500 l. Potassium chloride was varied from 0 to 100 mM. The enzyme ranged from 0.3 g/reaction for rhcFPGS to 3 g/reaction for R377A.
RESULTS
Evidence for Active Site Labeling by Iodoacetamide-IAM
inactivated rhcFPGS, with a loss of 30 -85% activity in 5 min, depending on the enzyme concentration during exposure (Fig.  2) . Inhibition of enzyme activity followed a biphasic time course, and the initial rapid phase was particularly noticeable at higher enzyme concentrations, with 80% enzyme inactivation within 0.5 min. (Fig. 2B ). In the presence of MgATP alone or with methotrexate, the inactivation of rhcFPGS by IAM was substantially reduced (Figs. 2A) . 2 The kinetics of binding of [ 14 C]IAM to rhcFPGS was also biphasic and reflected the time course of inhibition of enzyme activity (Fig. 2B ). During the rapid initial phase of enzyme inhibition, IAM labeled enzyme to a stoichiometry of about 1 mol/mol of enzyme. Interestingly, rhcFPGS that had reacted with 1 mol of IAM/mol of enzyme still had about 25% enzyme activity, and complete inhibition of enzyme activity required labeling to about 3 mol of reagent/mol of enzyme (Fig. 2B) . Hence, either IAM inactivated rhcFPGS by alkylating multiple amino acids in or close to the active site or by alkylating three reactive surface residues on peptides that 2 Control experiments indicated no appreciable direct reaction between IAM and ATP under these conditions (pH 7.5, 20°C).
FIG. 2.
A, inactivation of rhcFPGS by IAM. rhcFPGS was preincubated alone (E), with 3 mM ATP (छ), or with 3 mM ATP and 2 mM methotrexate (‚) at 20°C in 20 mM KCl, 10 mM MgCl 2 , 20 mM Na-HEPES, pH 7.5. After 5 min, freshly prepared IAM was added to 2 mM. IAM was not added to a parallel tube (Ⅺ). Aliquots of enzyme were removed at the indicated times and quickly assayed for enzyme activity. The ratio of enzyme activity remaining (E) to that present at time zero (E 0 ) was plotted against time. B, stoichiometry of binding of [
14 C]IAM to rhcFPGS. Purified rhcFPGS (1 nmol) was treated with 350 nmol of [ 14 C]IAM in 10 mM MgCl 2 , 20 mM KCl, 20 mM NaHEPES, pH 7.5. At the indicated times, the reaction was stopped by the addition of 50 mM 2-ME, and the fractional enzyme activity remaining (E/E 0 ) and the stoichiometry of [ 14 C]IAM covalently bound/mol of the enzyme ( q) were determined.
became mobile following substrate binding, burying the reactive residues away from solvent. Because either possibility would indicate a crucial role in the behavior of this enzyme, the peptides to which IAM was binding were identified.
Peptide Analysis-After an initial proteolytic digestion of [ 14 C]IAM-inactivated FPGS, several of the tryptic peptides detected at A 220 in the effluent of a C-8 HPLC column were labeled with 14 C (Fig. 3, A and B) . In the presence of ATP and methotrexate, the amount of peptide-bound 14 C derived from IAM that was detected in tryptic digests of rhcFPGS was substantially decreased, and interestingly, every labeled peptide peak was diminished (Fig. 3B) . When the several radioactive peptides labeled in the absence of ATP (Fig. 3B) were pooled and again treated with trypsin, a simpler HPLC profile of labeled peptides was observed (Fig. 3C) , which did not further simplify with more extensive tryptic digestion. Each of the three major labeled peptides (Fig. 3C ) was repetitively chromatographed on a C-18 HPLC column until the profile of radioactivity and of A 220 indicated the presence of a single labeled peptide.
A microsequence from each of the three labeled peptides unambiguously matched peptide sequences predicted by the cDNA sequence. Automated sequencing of peptide I stopped after 12 cycles, and the data fit a tryptic peptide deduced from the cDNA sequence of rhcFPGS corresponding to the cytosolic FPGS peptide G 66 STCAFTECILR 77 . The majority of the radioactivity associated with peptide I was liberated in the cycle when the phenylthiohydantoin-derivative of cysteine 69 was released, although a small amount of radioactivity was also observed at cysteine 74. Electrospray ionization mass spectrometry (EIMS) (9) of peptide I revealed two mass ions; the major peak, at m/z ϭ 1413.6, corresponded to the molecular weight calculated for the peptide sequence GSTCAFTECILR. Automated sequencing of peak II clearly indicated the peptide sequence LLQPC, then stopped after the fifth cycle. This amino acid sequence matched that of the rhcFPGS tryptic fragment starting at residue L 385 and ending with C 389 , as deduced from the cDNA sequence. The last amino acid released during this sequencing, a cysteine, also contained the radioactivity associated with this peptide. As expected, the largest molecular ion in the EIMS fragmentation pattern of Peak II had the molecular weight (629.4) calculated for the peptide LLQPC. Peak III was found to contain a single peptide of 21 amino acids, which unambiguously matched the sequence expected for tryptic cleavage at Arg-327 and at Arg-348 of rhcFPGS. The radioactivity was associated with Cys-346 in this peptide. EIMS of peak III indicated two molecular ions at 1130 and 753.3 m/z, corresponding to m/2e and m/3e for a peptide of 2260 daltons, the calculated mass of the FPGS peptide 328 GPLTWYLDGA-HTASSAQACVR 348 . It was of interest to determine whether the early phase of reaction of enzyme with IAM ( Fig. 2) involved the modification of a single very reactive cysteine. To address this question, rhcFPGS that had been incubated with IAM for 30 s, after which a single mol of reagent had reacted per mol of enzyme (Fig. 2B) , was exhaustively digested with trypsin, and the labeled tryptic peptides were subjected to HPLC. Surprisingly, this experiment revealed that all three peptides (I, II, and III; Fig. 3C ) reacted during the initial labeling event. We concluded that labeling of 1 mol of any of these reactive cysteines substantially inhibited the enzyme and also decreased the accessibility of the other two cysteines for reaction, as indicated by the decreased slope of both functions shown in Fig. 2B after the initial phase of reaction.
Selection of Amino Acid Residues for Mutagenesis-A homology comparison of the sequences of FPGS from 12 species indicated a number of residues immediately adjacent to these IAM-sensitive cysteines that have been completely conserved throughout evolution (Fig. 4) . It was noted that the three IAMsensitive cysteines were not found in the bacterial FPGS sequences and, hence, appear unlikely to be essential to the FPGS reaction, which has similar but not identical characteristics in bacteria and higher species. Peptide I was clearly part of the ATP binding site (11, 12) and was not studied further, whereas peptides II and III were potentially part of the folate or glutamate binding sites, which have not yet been experimentally definable. Because these peptides were clearly solventexposed and were potentially located in the active site, several adjacent charged amino acids that were particularly conserved in peptides II and III were selected for site-directed mutagen- esis. Each of these residues (Asp-335, His-338, Asp-376, Arg-377, and Asp-378) were mutated to alanines, as was Cys-346, one of the three iodoacetamide-sensitive residues, and Lys-384, an amino acid conserved only among higher species (Fig. 4) . Selection of these amino acids as potential active site residues based on homology considerations was later supported by the structure of L. casei FPGS complexed with ATP, for which the x-ray coordinates were released while this manuscript was being reviewed.
Functional Complementation of AUXB1 Cells by FPGS Mutants-The
Chinese hamster ovary derivative, AUXB1, is auxotrophic for an exogenous source of the end products of folate metabolism, thymidine and purines, as a result of a lack of expression of FPGS activity (13, 14) . cDNA constructs encoding seven mutant FPGS species were cloned into the pcDNA3 vector, and the resultant plasmids were co-transfected into AUXB1 cells along with pY3, a plasmid encoding resistance to hygromycin B (7). Complementation of the AUXB1 phenotype by transfection of a cDNA encoding wild-type rhcFPGS or these several mutant enzymes is shown in Fig. 5 . Transfection of the C346A mutant resulted in the formation of colonies in medium lacking thymidine and purines (Fig. 5) , indicating that Cys-346 was not required for FPGS enzyme activity; the colonies that were formed looked morphologically identical to those formed in the control rhcFPGS plates. Plasmids encoding the H338A, D376A, D378A, and K384A proteins partially supported the growth of AUXB1 cells, with 50 -75% of the number of colonies on the wild-type rhcFPGS control. The colonies in plates transfected with these mutants grew vigorously, similar to those for rhcFPGS transfectants. However, plates transfected with R377A had far fewer colonies, and the colonies were sparse clusters of rounded cells that were poorly attached to the plates. It was concluded that this mutant barely supported the growth of AUXB1 cells. A few very small colonies were formed from cells transfected with the D335A mutant, and those consisted of a small number of large, rounded cells that stained poorly, which was very similar to the cell debris remaining on plates transfected with pY3 alone. Hence, transfection of these mutated FPGS species into cells lacking endogenous FPGS activity identified two residues, Asp-335 and Arg-377, which appeared central to FPGS activity in vivo.
FPGS Activity of the Mutant Proteins Expressed in Insect Cells-The mutant FPGS cDNA sequences were inserted into recombinant baculoviruses, and the proteins were expressed in Sf9 insect cells. SDS-polyacrylamide gels of protein from lysates of insect cells infected with viruses encoding each of the mutant FPGS species and of wild-type FPGS demonstrated comparable levels of expression of a protein at 60 kDa, the molecular mass of FPGS (Fig. 6A) . The level of FPGS activity in the protein extracted from these cells is shown in Fig. 6B . As expected from the AUXB1 transfection results, both D335A and R377A mutant proteins did not have significant FPGS activity under these standard assay conditions, whereas insect cells expressing the C346A mutant FPGS contained FPGS enzyme activity comparable with that of extracts expressing the wildtype FPGS. Likewise, FPGS activities found in cells expressing the D376A, D378A, and K384A mutants were only slightly lower than control, recapitulating the results of the AUXB1 transfection experiments. The most interesting result was seen with the H338A mutant, which had only 0.3% activity compared with the wild-type FPGS control, in striking contrast to the fact that the H338A mutation complemented the FPGS deficiency of AUXB1 cells when transfected under the cytomegalovirus promoter of pcDNA3 (Fig. 5) . These experiments also implied that all the FPGS mutant enzymes were expressed equally well and were stable in Sf9 cells (Fig. 6A) . Hence, larger cultures of insect cells were infected with the cloned baculovi- 
FIG. 5. Functional complementation of AUXB1 cells by rhcF-PGS and its mutants.
Cells were co-transfected with pcDNA3 constructs of wild-type or mutant rhcFPGS and with pY3, a vector carrying the hygromycin B resistance marker. Colonies were selected for their ability to produce functional FPGS and resistance to hygromycin B and were fixed, stained, and counted on day 15. The data represent the mean number of colonies from two separate experiments, each containing three to four dishes for each condition. For details see "Materials and Methods". ruses expressing these enzyme species and were used as a source of enzymes for further kinetic analyses. The seven mutant proteins and rhcFPGS protein were brought to Ͼ95% purity by the three-step procedure developed (4) in previous work on the wild-type rhcFPGS. All of the proteins were found to behave exactly the same as rhcFPGS in (NH 4 ) 2 SO 4 precipitation, gel filtration, and DEAE-Sephacel ion exchange steps. Roughly equivalent yields of the purified proteins (4 -6 mg/ 800-ml culture of Sf9 cells) were obtained, particularly when the insect cells were grown on medium supplemented with thymidine and hypoxanthine.
Steady State Kinetic Studies Using Aminopterin as a Folate Substrate-A standard assay based on charcoal adsorption of reaction products was used to estimate the kinetic constants of the mutant enzymes for all three substrates. Aminopterin was found to be an ideal folate substrate for these initial velocity studies. It was an excellent substrate for conversion to the diglutamate by wild type rhcFPGS (K m ϭ 9 M), but is not easily converted to higher polyglutamates by the human enzyme. 3 Under these experimental conditions, four of the mutant enzymes (C346A, D376A, D378A, and K384A) were found to be equally as good catalysts as the wild-type enzyme, with k cat values that were equivalent to that of rhcFPGS (Table I ). The K m value measured for aminopterin was not different from that of control rhcFPGS for C346A, D378A, and K384A and differed only by a factor of three for D376A; the K m value of ATP was not significantly different from control for any of these enzymes. The K m for glutamic acid did not change with the K384A and C346A mutations, but it was significantly higher for D378A and D376A. The increased K m for glutamic acid found for the D376A and D378A mutants appeared to be biologically meaningful, particularly in view of the fact that, when the arginine at the intervening 377 position was changed, the K m for glutamic acid was dramatically altered.
The kinetic behaviors of three mutant enzymes, D335A, H338A, and R377A, were informative. These proteins had negligible enzyme activity with the standard assay based on incorporation of 1 mM [ 3 H]glutamic acid into aminopterin diglutamate; V max values were estimated to be decreased by 100-, 350-, and 1 ϫ 10 4 -fold for these three enzymes, respectively. To obtain kinetic estimates for D335A, H338A, and R377A, a 1000-fold higher enzyme concentration (1.67 M) was used to partially overcome the extremely low V max values. For R377A, D335A, and H338A, under very high enzyme conditions, the K m values for aminopterin and ATP could be estimated, but the K m for glutamic acid could only be set at Ͼ10 mM.
These results compelled us to develop an alternative assay based on the conversion of [ 3 H]aminopterin to its diglutamate and on the use of HPLC for quantitation of the product formed. A 3-m reverse phase HPLC column separated aminopterin from its diglutamate by 4.5 min, allowing a clean separation of the product from substrate. Using this technique, it was found that the K m values of glutamic acid for D335A, H338A, and R377A were very high, ranging from 90 to 350 mM, or 400 to 1500 times the K m for rhcFPGS (Table I ). The K m estimates for ATP and aminopterin measured for D335A, H338A, and R377A using this HPLC assay (Table I ) and glutamic acid concentrations up to 400 mM 4, 5 were comparable with those obtained under standard conditions, but the k cat value for D335A was now comparable with those of rhcFPGS, and that of H338A was only 2-fold lower (Table I) . Only for mutant R377A was there a bona fide k cat effect; the k cat of this enzyme was about 5% that of rhcFPGS. Overall, we concluded that all three of the enzymes that were catalytically inactive under standard conditions had a different set of changes in kinetics. D335A appears to be binding all three substrates poorly, whereas the H338A mutation affected only the binding of glutamic acid, and neither of these mutants induced any major change in k cat . R377A was a poorer catalyst because of both a massive increase in the K m for glutamic acid and a 20-fold decrease in k cat , yet this enzyme had a 10-fold lower K m for ATP than rhcFPGS.
Polyglutamation of Dideazatetrahydrofolate in Vitro-The ability of the mutant enzymes to add multiple moles of glutamate to DDATHF was studied by HPLC in reactions carried out at an enzyme concentration that simulated cellular concentrations of FPGS. Following a 2-h incubation of 10 Ϫ7 M 6 rhcF-PGS with 5 M DDATHF, a range of products was found that cochromatographed with authentic tri-, tetra-, penta-, and hexaglutamate derivatives of parent compound, with no detectable diglutamate (Table II) . The same distribution of reaction products were formed by the C346A and K384A mutant en-3 P. C. Sanghani and R. G. Moran, unpublished observations. 4 Pilot studies demonstrated that glutamate did not cause substrate inhibition with wild-type FPGS at concentrations less than 600 mM. 5 The increased activity of mutants D335A, H338A, and R377A at very high glutamic acid (prepared as the sodium salt) might have been a reflection of the sodium content of reaction mixes, rather than a glutamic acid K m effect. However, when the effect of increased monovalent ion concentrations was studied at a fixed glutamic acid concentration (5 mM), these mutant enzymes did not display enhancement of enzyme activity by high Na ϩ concentration (data not shown). Thus, the results shown in Table II are due to glutamic acid K m effects. Interestingly, these experiments demonstrated that increased levels of either Na ϩ or K ϩ inhibited the FPGS reaction; K ϩ was substantially more inhibitory then Na ϩ . This study suggested that higher glutamate concentrations were able to compete with the inhibitory effects of excessive monovalent anions. 6 This value represents the level of FPGS in the cytoplasm of CEM leukemic cells. zymes. Mutant enzymes D376A and D378A also formed extensive, long chain polyglutamates and extended these side chains to longer lengths than the wild-type enzyme. No products could be detected in reactions with either R377A or D335A. Measurable levels of pentaglutamate were formed in reactions catalyzed by mutant H338A, despite the fact that no di-, tri-, or tetraglutamate products were found.
Surprisingly, all three enzymes, D335A, H338A, and R377A, which could not use either aminopterin (Table I) or DDATHF (Table II) as substrates, showed substantial enzyme activity for the diglutamate of DDATHF (Table II) . By far the most active was mutant H338A, which converted most of the substrate to long chain oligoglutamates during 2 h, which was quite a bit higher activity than seen with DDATHF under identical conditions. Similar reactions using the triglutamate of DDATHF as a substrate showed results very similar to those found using the diglutamate (data not shown). We concluded that the mutations in FPGS had the greatest effect on the FPGS reaction converting a monoglutamate to a diglutamate, and less effect on subsequent additions of glutamate. This observation implies intrinsic differences in the mechanism of the FPGS reaction with monoglutamate substrates and with subsequent reactions.
In Vitro Polyglutamation Parallels the Pattern of Complementation Seen in AUXB1 Cells-The polyglutamation pattern of (6R)-DDATHF was examined for D335A, H338A, and R377A at high glutamic acid concentrations. At 5 mM glutamic acid, rhcFPGS rapidly synthesized long chain polyglutamates of DDATHF. The reaction products contained mainly 3-5 mol of glutamate/mol of pteridine after 10 min of incubation, and exclusively, 6 -8 mol of glutamate by 2 h. Similar reactions with mutants D335A, H338A, and R377A did not yield products at 10 min and yielded only minimal products at 2 h; only 10% of (6R)-DDATHF was converted to pentaglutamate for the H338A mutant, Ͻ2% diglutamate for R377A, and no polyglutamation was seen for D335A. However, increasing the glutamic acid concentration to 400 mM increased the polyglutamation for D335A, H338A, and R377A, with DDATHF quantitatively converted to penta-and hexaglutamate products by 2 h for H338A, whereas R377A converted 25% of DDATHF to tetra-and pentaglutamate forms in 2 h. Again, D335A was the least active enzyme even at 400 mM glutamic acid, and it converted less than 10% of DDATHF to products with greater than 2 glutamates/mol of pteridine in 2 h. This pattern of enzyme activity at high glutamic acid parallels the ability of these mutant enzymes to complement the growth of AUXB1 acid to DDATHF and to the diglutamate of DDATHF Either (6R)-DDATHF (5 M) or the diglutamate of (6R)-DDATHF (5 M) was incubated with 2.5 g of the indicated species of FPGS for 2 h in 100 mM Tris buffer, pH 8.9, containing 5 mM glutamic acid, 30 mM KCl, 10 mM MgCl 2 , 5 mM ATP, and 0.15 mg/ml bovine serum albumin in a total volume of 500 l at 37°C. The samples were analysed by HPLC as described in the text. cFPGS, cytosolic FPGS. Dashes indicate no compound detected. 
kinetic constants of rhcFPGS and mutant FPGS species
The kinetic constants of (wild-type) rhcFPGS and of the several mutant enzyme species were determined at 37°C for the addition of glutamic acid to aminopterin and quantitation of the [ 3 H]aminopterin diglutamate product formed. For rhcFPGS, C346A, D376A, D378A, and K384A, [ 3 H]glutamic acid was the labeled substrate, and product was isolated by charcoal adsorption (12) . The V max value measured for D335A, H338A, and R377A with this assay was Ͼ500-fold lower than rhcFPGS using the charcoal adsorption-based assay at achievable concentration of [ 3 H]glutamic acid. Hence, [ 3 H]aminopterin was used as the labeled substrate for D335A, H338A, and R377A, and [ 3 H]aminopterin diglutamate product formed was isolated by HPLC. The assay buffer for both assays was 100 mM Tris, pH 8.9, containing 300 g/ml BSA, 30 mM KCl, and 10 mM MgCl 2 . Assay contents of the enzyme were varied from 1 to 20 nM. The values listed are the means of two to four independent determinations on separate days. For values averaged from three or more estimates, the average S.D. was 28% of the mean. 
0.025
a ATP was 5 mM, and aminopterin concentration was varied from 1.33 M to 1 mM. Glutamic acid was 1 mM in the charcoal assay and 400 mM in the HPLC assay.
b For the charcoal assay, aminopterin was 200 M, except for D335A for which it was held at 400 M; glutamic acid was 1 mM. For the HPLC assay, aminopterin was held constant at between 100 and 400 M, and glutamic acid was 400 mM. ATP was varied from 12.5 M to 2700 M.
c For the charcoal assay, aminopterin was 200 M and glutamic acid was varied from 50 M to 10 mM. For the HPLC assay, aminopterin was constant between 100 and 500 M, and glutamic acid was varied from 12 to 400 mM. For both assays, ATP was held at 5 mM. cells (Fig. 5) . If enzyme were exposed to a high glutamic acid concentration in vivo, the observed patterns of growth of AUXB1 cells by H338A, D335A, and R377A would be expected.
Requirement for Monovalent Ions-For many synthetases, monovalent ions are involved in the binding of a negatively charged substrate, effectively reducing the net negative charge for the bound substrates in the active site. Hence, we questioned whether the increase in the K m of glutamic acid for mutants D335A, H338A, and R377A involved poor binding of monovalent cations. All three of these mutant enzymes, as well as wild-type rfcFPGS, were inactive in the absence of K ϩ , demonstrating the absolute dependence of the FPGS reaction on K ϩ (Fig. 7) . The K m value of K ϩ for rhcFPGS was very low (0.5 mM), with inhibition above 7.5 mM K ϩ . Interestingly, the K m of K ϩ for the D335A mutant was 40 mM, and no substrate inhibition was detected at K ϩ concentrations as high as 100 mM (Fig. 7) . In contrast, the K m of K ϩ for H338A was 4.8 mM and R377A was 2.2 mM, and unlike D335A, both H338A and R377A exhibited substrate inhibition at higher concentrations. The increased K m values for K ϩ with all three of these mutant enzymes are compatible with a role in positioning monovalent cations within the active site.
DISCUSSION
This work was begun in an effort to place the active site of human FPGS within the 545 amino acids of the primary sequence. Initial experiments indicated the presence of three highly reactive cysteine residues on the human enzyme, which were largely protected from alkylation by iodoacetamide in the presence of ATP and folates. Each IAM-reactive, and hence solvent-exposed, cysteine was immediately adjacent to peptides that contained highly conserved amino acids. One of these regions, which was immediately adjacent to and overlapping with peptide I (Fig. 4) , could be identified by sequence homology as a Walker A half-site for binding of ATP (11) . This peptide was equivalent to a position in the L. casei enzyme, which has been shown to be involved in ATP binding by site-directed mutagenesis (12) . Hence, we presumed that the three reactive cysteines were in or very near the active site of human FPGS and were, when alkyated by IAM, capable of occluding substrate access to the active site. We focused on peptides II and III, whose functions were not known, and mutated the conserved anionic and cationic amino acids on these peptides, in search of residues that either were involved in binding of the other two substrates, glutamic acid and folates, or were directly involved in catalysis. Of the five residues chosen for mutation by these criteria (Asp-376, Arg-377, Asp-378, Asp-335, and His-338), our results implicate three (Asp-335, His-338, and Arg-377) in binding folates and/or glutamic acid and one (Arg-377) in the catalytic mechanism.
The effect of mutations D335A, H338A, and R377A on the binding of glutamic acid was substantial. We presume that all three amino acids donate hydrogen bonds to the placement of glutamic acid in the orientation requisite for catalysis (Fig. 8) . However, only the H338A mutant constituted a pure effect on the K m for glutamic acid. D335A also affected the other two substrates, and R377A decreased the k cat by 95%. This finding appears to explain the fact that the H338A mutant cDNA could partially complement the AUXB1 phenotype in vivo, whereas the D335A and R377A mutants did not support AUXB1 cell growth.
The FPGS reaction is formally very similar to that catalyzed by glutamine synthetase (GS) and ␥-glutamylcysteine synthetase; all three enzymes carry out the ATP-dependent formation of an amide bond between the ␥-carboxyl of a (substituted) glutamic acid and a (substituted) amine. For FPGS, the substituted glutamic acid is the folate, i.e. the N-pteroyl-glutamic acid analog, and the reacting amine is the ␣-amino group of the incoming glutamic acid. This analogy is quite useful, because the GS reaction has been extensively studied using site-directed mutagenesis coupled with structural analysis. Aspartate, histidine, and glutamic acid residues have been identified in GS, which are responsible for binding of the metal ions involved in the reaction (15) . The mutation of Asp-50 in the Escherichia coli GS to alanine marginally increased the K m values for glutamic acid and ATP, but it dramatically increased the K m for the incoming amine, that is, for the ammonium ion, by 550-fold (16) . It has been proposed that GS Asp-50 plays a FIG. 7 . Potassium stimulation of the reaction catalyzed by FPGS mutants. Enzyme reactions were carried out in 0.5 M Tris, pH 8.9, 400 mM glutamic acid, 50 mM aminopterin, 5 mM Tris-ATP, 10 mM MgCl 2 , 500 M 2-ME, and 0.6 mg/ml bovine serum albumin at 37°C for 30 min. The enzyme content of the reactions was varied to allow a measurable rate of reaction and was 0.3 g for rhcFPGS, 0.4 g for H338A, 0.9 g for D335A, and 3 g for R377A. Data for K ϩ concentrations prior to the onset of inhibition of enzyme were used for fitting to Michaelis constants. Samples were analyzed by HPLC as described under "Materials and Methods." Table I imply that all three of these residues are involved in the positioning of glutamic acid in the active site, and that Asp-335 and His-338 form bonds with K ϩ . His-338 and/or Asp-335 are proposed to affect abstraction of a proton during attack of the amino function of the incoming glutamic acid on the ␥-carbon of the folyl-␥-phosphate, and Arg-377 is proposed to play a central role in stabilization of the mixed anhydride intermediate. The two-dimensional depiction of these effects obscures the proximity of the ␥-carbonyl carbon to the amino group of the incoming glutamic acid, which is more readily suggested by Fig. 9. major role in the binding and deprotonation of the ammonium ion, although the Asp-50 mutation had only minor effects on k cat (17) . We propose that both His-338 and Asp-335 play similar roles in FPGS (Fig. 8) , presumably by forming an ion pair with the incoming ␣-amino group of glutamic acid and by involvement in the abstraction of a proton from this amine during reaction. Likewise, the placement of highly conserved residue Asp-131 in the Salmonella typhimurium GS structure positions it within binding distance of a divalent metal ion and of the ␣-amino group of glutamic acid, leading to the proposal that it is involved in the placement of the active site metal ion and glutamic acid in GS (15, 17) , a role we propose for Asp-335 in rhcFPGS. FPGS D335A disrupts the binding of glutamic acid, increasing it's K m by 400-fold and the K m for K ϩ by 80-fold. Hence, the effects of Asp-335 on binding of ATP and folate could be either direct or secondary to poor binding of K ϩ . Two arginine residues play key roles in bacterial GS (15); GS Arg-321 binds the ␣-carboxyl of the glutamic acid (the equivalent to the side chain of the folate substrate for FPGS), and structural and mutagenesis studies (15, 18) identify S. typhimurium GS Arg-359 as a key residue for orientation of the ␥-carboxyl group of the glutamic acid and for stabilization of the mixed anhydride transition state intermediate. It would seem likely from our results that FPGS Arg-377 is involved in orientation of the incoming glutamic acid within the active site and might well interact with and stabilize the phosphorylated intermediate of the FPGS reaction, thus explaining the 95% drop in k cat in the R377A mutant. These hypothetical roles of Asp-335, His-338, and Arg-377 in the FPGS reaction are summarized in Fig. 8 , and could form a context in which to examine the mechanism of the FPGS reaction in further mechanistic and structural studies on the human enzyme.
Recently, the crystal structure of L. casei FPGS bound to Mg-ATP was reported (5); the coordinates of this structure were released while this manuscript was under review. When the amino acids in the L casei structure equivalent to human Cys-69, Cys-389, and Cys-346 were examined in a humanized molecular model of this structure (not shown), two of these three reactive cysteines were positioned in the only entrance to the active site of this enzyme, the third was adjacent to the p-loop binding site for ATP, and all three cysteines were close to each other in space. Once modified by iodoacetamide, the access of substrates to the active site would be hindered, and modification of any one of these cysteines would decrease access of iodoacetamide to the other two cysteines. Although the folate and glutamic acid binding sites cannot be directly determined from the L. casei FPGS structure, the binding site of folates was deduced by the authors by virtue of exquisite similarity of a distinct C-terminal domain of L. casei FPGS to the structure (but, remarkably, not the sequence) of dihydrofolate reductase (5) . A hydrophobic cleft in the C-terminal domain of the FPGS structure was evident in precisely the same region as the binding site for methotrexate in dihydrofolate reductase. This region lay between the 10th ␣-helix (A10) and ␤ strands B12 and B16 and was tentatively identified (5) as the binding site for folates in FPGS. The L. casei residues (Asp-313 and His-316) homologous (Fig. 4) to two of the human FPGS residues that we identify herein, Asp-335 and His-338, lie on a linker between A10 and the preceding ␤-strand (B12), placing them between the proposed (5) folate binding site and the phosphates of ATP (Fig. 9) . His-338 and Asp-335, along with Arg-377, define a binding surface for glutamic acid (Table I) ; the D335A mutation affected the binding of all three substrates, lending credence to the likelihood that Asp-335 is involved in orienting all of the substrates for catalysis, either directly, or indirectly through bridges to K ϩ . Arg-377 of the human FPGS is located on the peptide analogous to the sevenresidue peptide (amino acids 341-347) between ␣-helix A12 and ␤-strand B13 of the L. casei structure (5), whose exact position cannot be determined from the available crystallography coordinates because of its high mobility. From inspection of the L. casei structure (Fig. 9) , L casei Lys-346 (equivalent to human Arg-377) would be predicted to be quite close to the binding site for glutamate acid, the proposed binding site for FIG. 9 . Proximity of amino acids equivalent to human Arg-377, His-335, and Asp-338 in the crystal structure of L. casei FPGS and the deduced location of the catalytic site. The crystal structure of L. casei FPGS (5) was downloaded from the Protein Data Base (PDBID ϭ 1 FGS) and is presented in ribbon form (yellow-green) using the program Sybyl 6.4. The location of a pyrophosphate from ATP is indicated in red and yellow and labeled POP999. ␣-Helix 10 (A10) is colored red in this diagram, and ␣-helix 12 is immediately below A10. Peptide NGKGS, the core of the p-loop, is shown in the blue space-filling display. L. casei FPGS His-316 and Asp-313, the equivalent residues of human His-338 and Asp-335, respectively (Fig. 4) , are shown in the space-filling mode, as are Tyr-348 and Gly-341, the last amino acids defined in Ref. 5 of a mobile peptide containing L casei Lys-346, the equivalent of human Arg-377 (Fig. 4) . Human Asp-335, His-338, and Arg-377 form at least part of the binding site for incoming glutamic acid. The location of the heterocycle and sugar moieties of ATP are not discernible from the x-ray structure and were proposed (5) to be in the fold between the N-terminal and C-terminal domains. The pyrophosphate seen in this structure were presumed to be the ␣-and ␤-phosphates of bound ATP (5); the ␥-phosphate is presumed to project downward and to the left, more weakly held in place by the p-loop. The proposed (5) position of the folate substrate would be between the A10 and A12 helices and ␤ strands 12 and 16, which would place one end of the folate (presumably the ␥-carboxyl group of the side chain) between and above Tyr-348 and Gly-341.
folate, and the putative position of the ␥-phosphate of ATP (Fig.  8) , supporting a central role for Arg-377 in enzyme catalysis.
In conclusion, the three amino acid residues identified as essential to the binding of glutamic acid and/or folate for human FPGS and for catalysis direct our attention to one restricted region of the space within the FPGS structure as the region responsible for the approximation of the segments of all three substrates involved in the FPGS reaction. The combination of additional structural data and site-directed mutagenesis will be needed to understand the chemistry of this reaction and the modes of binding of both folate monoglutamates and polyglutamates to this active site. The overwhelming similarities between bacterial and mammalian FPGS species suggest that the major aspects of the reaction carried out by both will be similar, if not identical. However, the L. casei and human enzymes have a limited degree of sequence homology, 7 so that the crystal structure of a mammalian FPGS will be required for many purposes; the comparison of bacterial and mammalian FPGS structures will certainly teach some additional functional lessons. Of the 117 extra amino acids inserted in the human enzyme over those found in the L. casei FPGS, 96 are in the C-terminal domain, which is only 132 amino acids long in the L. casei FPGS but 228 in the human enzyme. Hence, it is in the C-terminal domain that the differences between bacterial and mammalian FPGS are to be expected.
